Clinical Trial

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 4, 2026 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase Ib/II, open label clinical study to evaluate the safety, tolerability and antitumor activities of IN10018 in combination with standard chemotherapy in subjects with high-grade serous ovarian cancer (including fallopian tube cancer and primary peritoneum cancer, collectively defined as ovarian cancer).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-09-20; most recent amendment 2026-05-01.
Trial Details
NCT Number NCT05551507
Lead Sponsor InxMed (Shanghai) Co., Ltd.
Conditions Platinum-resistant Ovarian Cancer
Enrollment 150 participants
Start Date 2020-07-27
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-04